INT298211

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.00
First Reported 2010
Last Reported 2010
Negated 2
Speculated 1
Reported most in Abstract
Documents 1
Total Number 4
Disease Relevance 1.23
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (MPHOSPH6) RNA binding (MPHOSPH6) nucleus (MPHOSPH6)
cytoplasm (MPHOSPH6)
MPHOSPH6 (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 24 5.00 Very Low Very Low Very Low
Inflammation 16 5.00 Very Low Very Low Very Low
COX2 8 5.00 Very Low Very Low Very Low
COX-2 inhibitor 8 5.00 Very Low Very Low Very Low
cytokine 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Lung Cancer 180 98.12 Very High Very High Very High
Cancer 24 68.76 Quite High
Malignant Neoplastic Disease 16 67.12 Quite High
INFLAMMATION 20 5.00 Very Low Very Low Very Low
Hyperplasia 4 5.00 Very Low Very Low Very Low
Apoptosis 4 5.00 Very Low Very Low Very Low
Solid Tumor 4 5.00 Very Low Very Low Very Low
Non-small-cell Lung Cancer 4 5.00 Very Low Very Low Very Low
Disease 4 5.00 Very Low Very Low Very Low
Immunotherapy Of Cancer 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In both cell lines MPP89 and Ist-Mes-1, association of the two drugs did not act on p-AKT, confirming an antagonistic effect of gefitinib in combination with rofecoxib.
Neg (not) Regulation (act) of MPP89
1) Confidence 0.00 Published 2010 Journal Mol Cancer Section Body Doc Link PMC2828989 Disease Relevance 0.20 Pain Relevance 0
No change in p-AKT in Ist-Mes-1 and MPP89 was observed after treatment with gefitinib alone and in combination with rofecoxib.


Neg (No) Regulation (change) of MPP89
2) Confidence 0.00 Published 2010 Journal Mol Cancer Section Abstract Doc Link PMC2828989 Disease Relevance 0.33 Pain Relevance 0
To determine the effect of gefitinib on the phosphorylation status of EGFR, Ist-Mes-1, Ist-Mes-2 and MPP89, cells were seeded in T25 flask in full culture media for 24 h. 45 mins after the addition of gefitinib, EGF (final concentration 100 ng/ml) was added.
Spec (determine) Regulation (effect) of MPP89
3) Confidence 0.00 Published 2010 Journal Mol Cancer Section Body Doc Link PMC2828989 Disease Relevance 0.10 Pain Relevance 0
Only MPP89, Ist-Mes-1 and Ist-Mes-2 were sensitive to rofecoxib and showed growth-inhibition upon gefitinib treatment.
Regulation (sensitive) of MPP89
4) Confidence 0.00 Published 2010 Journal Mol Cancer Section Abstract Doc Link PMC2828989 Disease Relevance 0.60 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox